FOLFOXIRI

Uses your system voice; voice and rate in settings.

Snapshot

≈ 3 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

FOLFOXIRI is a chemotherapy regimen for the treatment of advanced colorectal cancer. The role of FOLFOXIRI in colorectal cancer has been reviewed. The chemotherapy regimen is made up of the following four drugs: * FOL – folinic acid (leucovorin), a vitamin B derivative that modulates/potentiates/reduces the side effects of fluorouracil; * F – fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis; * OX – oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis; * IRI – irinotecan (Camptosar), a topoisomerase inhibitor, prevents DNA from uncoiling and duplicating. It is usually given with bevacizumab, unlike FOLFIRINOX for treatment of advanced pancreatic cancer. Also, the doses (Day 1: irinotecan 165 mg/m2 IV, plus oxaliplatin 85 mg/m2 IV; Day 1: leucovorin 400 mg/m2; Days 1–3: fluorouracil 1,600 mg/m2/day × 2 days (total 3,200 mg/m2 over 48 hours) continuous infusion starting on day 1; Day 1: bevacizumab 5 mg/kg IV; repeat cycle every 2 weeks) are slightly dissimilar to FOLFIRINOX. Upfront FOLFOXIRI with bevacizumab can be followed by fluoropyrimidine with bevacizumab maintenance.

FOLFOXIRI is a chemotherapy regimen for the treatment of advanced colorectal cancer. The role of FOLFOXIRI in colorectal cancer has been reviewed. The chemotherapy regimen is made up of the following four drugs: FOL – folinic acid (leucovorin), a vitamin B derivative that modulates/potentiates/reduces the side effects of fluorouracil; F – fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis; OX – oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis; IRI – irinotecan (Camptosar), a topoisomerase inhibitor, prevents DNA from uncoiling and duplicating. It is usually given with bevacizumab, unlike FOLFIRINOX for treatment of advanced pancreatic cancer. Also, the doses (Day 1: irinotecan 165 mg/m2 IV, plus oxaliplatin 85 mg/m2 IV; Day 1: leucovorin 400 mg/m2; Days 1–3: fluorouracil 1,600 mg/m2/day × 2 days (total 3,200 mg/m2 over 48 hours) continuous infusion starting on day 1; Day 1: bevacizumab 5 mg/kg IV; repeat cycle every 2 weeks) are slightly dissimilar to FOLFIRINOX. Upfront FOLFOXIRI with bevacizumab can be followed by fluoropyrimidine with bevacizumab maintenance.

See also

FOLFIRI FOLFOX FOLFIRINOX IFL

References

Text derived from https://en.wikipedia.org/w/index.php?oldid=1301414122 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

3 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.